• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Coronavirus infection in an unvaccinated atopic dermatitis patient under ongoing dupilumab therapy: eczema flare-up, but moderate COVID-19 symptoms.

作者信息

Anasiewicz Natalie, Seeli Corsin, Brüggen Marie-Charlotte, Möhrenschlager Matthias

机构信息

Department of Dermatology, Hochgebirgsklinik, Herman-Burchard-Street 1, 7265 Davos Wolfgang, Switzerland.

Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.

出版信息

Allergo J Int. 2023 Feb 1:1-2. doi: 10.1007/s40629-023-00245-w.

DOI:10.1007/s40629-023-00245-w
PMID:36748045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9891745/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c3e/9891745/04310b7f7e09/40629_2023_245_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c3e/9891745/04310b7f7e09/40629_2023_245_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c3e/9891745/04310b7f7e09/40629_2023_245_Fig1_HTML.jpg

相似文献

1
Coronavirus infection in an unvaccinated atopic dermatitis patient under ongoing dupilumab therapy: eczema flare-up, but moderate COVID-19 symptoms.正在接受度普利尤单抗治疗的未接种疫苗的特应性皮炎患者感染冠状病毒：湿疹发作，但新冠症状较轻。
Allergo J Int. 2023 Feb 1:1-2. doi: 10.1007/s40629-023-00245-w.
2
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
3
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.度普利尤单抗治疗特应性皮炎患者的长期疗效：RELIEVE-AD研究3年随访结果
Dermatol Ther (Heidelb). 2023 Sep;13(9):2107-2120. doi: 10.1007/s13555-023-00965-5. Epub 2023 Aug 8.
4
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.度普利尤单抗为中度至重度特应性皮炎成人患者提供快速且持续的具有临床意义的缓解。
Acta Derm Venereol. 2021 Nov 10;101(11):adv00585. doi: 10.2340/actadv.v101.307.
5
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.度普利尤单抗治疗可使成人特应性皮炎患者的症状和生活质量在两年内持续改善。
Dermatol Ther (Heidelb). 2021 Dec;11(6):2147-2157. doi: 10.1007/s13555-021-00630-9. Epub 2021 Oct 29.
6
Association between short-term exposure to environmental air pollution and atopic dermatitis flare in patients treated with dupilumab.短期暴露于环境空气污染与接受度普利尤单抗治疗的患者特应性皮炎发作之间的关联。
JAAD Int. 2023 Feb 10;11:72-77. doi: 10.1016/j.jdin.2023.01.018. eCollection 2023 Jun.
7
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.阿泊替尼治疗重度和/或难治性特应性皮炎患者的疗效和安全性：随机 3 期 JADE COMPARE 试验的事后分析。
Am J Clin Dermatol. 2023 Jul;24(4):609-621. doi: 10.1007/s40257-023-00785-5. Epub 2023 May 22.
8
Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?度普利尤单抗治疗特应性皮炎：我们一直在寻找的万灵药？
Cureus. 2020 Apr 6;12(4):e7565. doi: 10.7759/cureus.7565.
9
Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: Real-life experience.度普利尤单抗在哥伦比亚中重度特应性皮炎成人患者中的有效性和安全性：真实世界经验
World Allergy Organ J. 2023 Apr 5;16(4):100763. doi: 10.1016/j.waojou.2023.100763. eCollection 2023 Apr.
10
Impact of COVID-19 on patients with atopic dermatitis.COVID-19 对特应性皮炎患者的影响。
Clin Dermatol. 2021 Nov-Dec;39(6):1083-1087. doi: 10.1016/j.clindermatol.2021.07.008. Epub 2021 Jul 17.

本文引用的文献

1
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.度普利尤单抗治疗中重度特应性皮炎患者的 COVID-19 症状减轻。
J Allergy Clin Immunol Pract. 2022 Jan;10(1):134-142. doi: 10.1016/j.jaip.2021.10.050. Epub 2021 Nov 1.
2
Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study.患有特应性皮炎并接受度普利尤单抗治疗的患者罹患 COVID-19 及其并发症的风险：一项基于人群的队列研究。
Immunol Res. 2022 Feb;70(1):106-113. doi: 10.1007/s12026-021-09234-z. Epub 2021 Oct 13.
3
The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study.
特应性皮炎患者感染新型冠状病毒肺炎的风险：一项回顾性队列研究。
J Am Acad Dermatol. 2022 Jan;86(1):243-245. doi: 10.1016/j.jaad.2021.09.061. Epub 2021 Oct 6.
4
Cutaneous Manifestations of COVID-19: An Experience From Oman.新型冠状病毒肺炎的皮肤表现：来自阿曼的经验
Cureus. 2021 Jul 27;13(7):e16667. doi: 10.7759/cureus.16667. eCollection 2021 Jul.
5
Atopic eczema.特应性皮炎
Curr Allergy Asthma Rep. 2006 Nov;6(6):445-7. doi: 10.1007/s11882-006-0016-5.
6
Viral infections in atopic dermatitis: pathogenic aspects and clinical management.特应性皮炎中的病毒感染：发病机制及临床管理
J Allergy Clin Immunol. 2003 Oct;112(4):667-74. doi: 10.1016/j.jaci.2003.07.001.
7
Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis.SCORAD指数的临床验证与指南：欧洲特应性皮炎工作组共识报告
Dermatology. 1997;195(1):10-9. doi: 10.1159/000245677.